Literature DB >> 2850212

Kappa antagonist properties of buprenorphine in the shock titration procedure.

S S Negus1, L A Dykstra.   

Abstract

Buprenorphine produced a dose-dependent antagonism of the selective kappa opioid agonist U50,488 in squirrel monkeys responding under the shock titration procedure. In one group of four monkeys, 0.003-0.01 mg/kg buprenorphine produced dose-dependent rightward shifts in the individual U50,488 dose-effect curves and increased the A50 value for U50,488 more than 2-fold in each monkey. Furthermore, 0.01 mg/kg buprenorphine antagonized a maximally effective dose of U50,488 in these monkeys. Buprenorphine (0.01-0.1 mg/kg) also produced rightward shifts in the group U50,488 dose-effect curve for a second group of three monkeys. Buprenorphine's antagonism of U50,488 was probably not a consequence of any mu opioid antagonist properties of buprenorphine in this procedure since (1) buprenorphine produced an inconsistent antagonism of the selective mu agonist fentanyl, and (2) the selective mu antagonist beta-funaltrexamine did not antagonize U50,488. These results support the hypothesis that buprenorphine has kappa antagonist activity in the shock titration procedure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850212     DOI: 10.1016/0014-2999(88)90149-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.

Authors:  Mark A Smith; Keith A Gordon; Christopher K Craig; Paul A Bryant; M Eric Ferguson; Adam M French; Jason D Gray; Jacob M McClean; Jonathan C Tetirick
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

Review 2.  Opioid receptors and signaling on cells from the immune system.

Authors:  Jean M Bidlack; Maxim Khimich; Amy L Parkhill; Sarah Sumagin; Baoyong Sun; Christopher M Tipton
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

Review 3.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 4.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

5.  Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.

Authors:  Margareeta Häkkinen; Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2011-09-17       Impact factor: 2.953

6.  Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.

Authors:  Sarah L Withey; Roger D Spealman; Jack Bergman; Carol A Paronis
Journal:  J Pharmacol Exp Ther       Date:  2019-08-14       Impact factor: 4.030

7.  Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats.

Authors:  S S Negus; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 8.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

9.  Interactions between mu and kappa opioid agonists in the rat drug discrimination procedure.

Authors:  S S Negus; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

10.  Single high-dose buprenorphine for opioid craving during withdrawal.

Authors:  Jamshid Ahmadi; Mina Sefidfard Jahromi; Dara Ghahremani; Edythe D London
Journal:  Trials       Date:  2018-12-10       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.